The Prognostic Significance of Jun Transcription Factors in Ovarian Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2013 Aug 15

PMID 23942796

Citations 17

Authors

Kerstin Eckhoff

Roland Flurschutz

Fabian Trillsch

Sven Mahner

Fritz Janicke

Karin Milde-Langosch

Affiliations

Soon will be listed here.

Abstract

Purpose: The Jun proteins (c-Jun, JunD and JunB) play an important role in the regulation of cell proliferation, apoptosis and angiogenesis. It is well established that these proteins participate in the carcinogenesis and progression in several tumour types. However, little is known about the prognostic significance of Jun proteins in patients with invasive epithelial ovarian carcinoma.

Methods: We analysed fresh-frozen tissues of 161 ovarian cancer patients by using Western blot analysis to investigate protein levels of JunB, JunD, c-Jun and phosphorylated c-Jun (pc-Jun Ser63). The results were correlated with clinicopathologic prognostic parameters and survival data.

Results: A high pc-Jun expression was significantly associated with shorter progression-free survival (14 vs. 16 months, p = 0.017) and overall survival (25 vs. 41 months, p = 0.038). In case of JunD, moderate protein levels were associated with a better prognosis, leading to longer progression-free and overall survival compared to weak or strong JunD expression (PFS in cases with weak/moderate/strong JunD expression: 14 vs. 19.5 vs. 16 months, p = 0.011; OAS: 32 vs. 42 vs. 35.5 months, p = 0.009). Multivariate Cox regression analysis confirmed an independent and significant impact of pc-Jun and JunD on the patient's prognosis.

Conclusions: Our results show that Jun proteins (pc-Jun and JunD) influence carcinogenesis and tumour progression, suggesting a significant role as prognostic predictors in human ovarian carcinoma.

Citing Articles

B cell function in patients with systemic lupus erythematosus is regulated by the upregulation of JunD.

Wu Y, Zhou Y, Zhu Q, Liu Y, Deng D, Zhang J Heliyon. 2024; 10(16):e35949.

PMID: 39220919 PMC: 11365431. DOI: 10.1016/j.heliyon.2024.e35949.

In Vitro Anticancer Activity of Novel Ciprofloxacin Mannich Base in Lung Adenocarcinoma and High-Grade Serous Ovarian Cancer Cell Lines via Attenuating MAPK Signaling Pathway.

Fawzy M, Abu-Baih R, Abuo-Rahma G, Abdel-Rahman I, El-Sheikh A, Nazmy M Molecules. 2023; 28(3).

PMID: 36770806 PMC: 9921546. DOI: 10.3390/molecules28031137.

Prognostic and clinicopathological significance of transcription factor c-Jun in hypopharyngeal squamous cell carcinoma: a 3-year follow-up retrospective study.

Huang Q, Ye M, Li F, Lin L, Hu C BMC Cancer. 2022; 22(1):1019.

PMID: 36163022 PMC: 9513886. DOI: 10.1186/s12885-022-10113-5.

Development and Validation of Hub Genes for Adrenal Aldosterone-Producing Adenoma by Integrated Bioinformatics Analysis.

Cai H, Chen S, Ke Z, Chen H, Zhu J, Lin T Int J Gen Med. 2022; 14:10003-10013.

PMID: 34984024 PMC: 8702988. DOI: 10.2147/IJGM.S330956.

Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer.

Ding Y, Labitzky V, Legler K, Qi M, Schumacher U, Schmalfeldt B Mol Oncol. 2021; 15(12):3578-3595.

PMID: 34060699 PMC: 8637562. DOI: 10.1002/1878-0261.13028.

References

Behrens A, Sibilia M, Wagner E . Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet. 1999; 21(3):326-9. DOI: 10.1038/6854. View

Mahner S, Baasch C, Schwarz J, Hein S, Wolber L, Janicke F . C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer. 2008; 99(8):1269-75. PMC: 2570515. DOI: 10.1038/sj.bjc.6604650. View

Karin M . The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995; 270(28):16483-6. DOI: 10.1074/jbc.270.28.16483. View

Wisdom R, Johnson R, Moore C . c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 1999; 18(1):188-97. PMC: 1171114. DOI: 10.1093/emboj/18.1.188. View

Johnson R, VAN LINGEN B, Papaioannou V, Spiegelman B . A null mutation at the c-jun locus causes embryonic lethality and retarded cell growth in culture. Genes Dev. 1993; 7(7B):1309-17. DOI: 10.1101/gad.7.7b.1309. View

Kimura R, Ishikawa C, Rokkaku T, Janknecht R, Mori N . Phosphorylated c-Jun and Fra-1 induce matrix metalloproteinase-1 and thereby regulate invasion activity of 143B osteosarcoma cells. Biochim Biophys Acta. 2011; 1813(8):1543-53. DOI: 10.1016/j.bbamcr.2011.04.008. View

Angel P, Karin M . The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991; 1072(2-3):129-57. DOI: 10.1016/0304-419x(91)90011-9. View

Milde-Langosch K, Janke S, Wagner I, Schroder C, Streichert T, Bamberger A . Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility. Breast Cancer Res Treat. 2007; 107(3):337-47. DOI: 10.1007/s10549-007-9559-y. View

Pfarr C, Mechta F, Spyrou G, lAllemand D, Carillo S, Yaniv M . Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras. Cell. 1994; 76(4):747-60. DOI: 10.1016/0092-8674(94)90513-4. View

10.

Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M . 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005; 16 Suppl 8:viii7-viii12. DOI: 10.1093/annonc/mdi961. View

11.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.027. View

12.

Weiss C, Schneider S, Wagner E, Zhang X, Seto E, Bohmann D . JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. EMBO J. 2003; 22(14):3686-95. PMC: 165634. DOI: 10.1093/emboj/cdg364. View

13.

Davis R . Signal transduction by the JNK group of MAP kinases. Cell. 2000; 103(2):239-52. DOI: 10.1016/s0092-8674(00)00116-1. View

14.

Derijard B, Hibi M, Wu I, Barrett T, Su B, Deng T . JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994; 76(6):1025-37. DOI: 10.1016/0092-8674(94)90380-8. View

15.

Le-Niculescu H, Bonfoco E, Kasuya Y, Claret F, Green D, Karin M . Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol Cell Biol. 1998; 19(1):751-63. PMC: 83932. DOI: 10.1128/MCB.19.1.751. View

16.

Jochum W, Passegue E, Wagner E . AP-1 in mouse development and tumorigenesis. Oncogene. 2001; 20(19):2401-12. DOI: 10.1038/sj.onc.1204389. View

17.

Zhou H, Gao J, Lu Z, Lu L, Dai W, Xu M . Role of c-Fos/JunD in protecting stress-induced cell death. Cell Prolif. 2007; 40(3):431-44. PMC: 6496388. DOI: 10.1111/j.1365-2184.2007.00444.x. View

18.

Hein S, Mahner S, Kanowski C, Loning T, Janicke F, Milde-Langosch K . Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines. Oncol Rep. 2009; 22(1):177-83. DOI: 10.3892/or_00000422. View

19.

Mathas S, Hinz M, Anagnostopoulos I, Krappmann D, Lietz A, Jundt F . Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 2002; 21(15):4104-13. PMC: 126136. DOI: 10.1093/emboj/cdf389. View

20.

Milde-Langosch K . The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 2005; 41(16):2449-61. DOI: 10.1016/j.ejca.2005.08.008. View